2025-12-25 - Analysis Report
Okay, here's a comprehensive report on Eli Lilly (LLY) based on the provided data:

**1) Return Rate vs. S&P 500 (VOO)**

*   **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.
*   **LLY Cumulative Return:** 305.60%
*   **VOO Cumulative Return:** 100.88%
*   **Divergence:** 204.7 (Relative Divergence: 84.5)

**Analysis:**

LLY has significantly outperformed the S&P 500 (VOO).  The cumulative return divergence is substantial. The relative divergence of 84.5 indicates that the current divergence is relatively high compared to its historical range. This suggests that LLY's outperformance is near the upper end of its historical trend.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2015-2017  | 11.0%  | 76.1%  | -17.0% | -0.0 | 76.1   |
| 2016-2018  | 39.0%  | 68.9%  | 24.0%  | -0.0 | 104.3  |
| 2017-2019  | 41.0%  | 68.9%  | 19.0%  | 0.4  | 118.4  |
| 2018-2020  | 34.0%  | 79.8%  | 10.0%  | 0.4  | 152.1  |
| 2019-2021  | 53.0%  | 79.8%  | 7.0%   | 0.5  | 248.9  |
| 2020-2022  | 64.0%  | 79.8%  | 65.0%  | 0.4  | 329.7  |
| 2021-2023  | 125.0% | 78.9%  | 124.0% | 0.2  | 525.3  |
| 2022-2024  | 134.0% | 81.2%  | 113.0% | 0.2  | 695.6  |
| 2023-2025  | 197.0% | 83.5%  | 132.0% | 0.2  | 965.5  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  The CAGR has increased significantly in recent years, showing very strong growth momentum.
*   **MDD (Maximum Drawdown):** The MDD has remained relatively high.
*   **Alpha:** The consistently positive and, in recent periods, very high alpha values indicate that LLY is generating returns independent of the market.
*   **Beta:** The Beta values are near or below zero, suggesting that LLY's price is not highly correlated with the S&P 500.
*   **Capital:** Market capitalization grew sharply from 76.1B to 965.5B, driven by strong returns.

**2) Recent Stock Price Fluctuations**

*   **Close:** 1071.44
*   **Last Market Data:** Price: 1076.98, Previous Close: 1071.64, Change: 0.5
*   **5-day SMA:** 1057.32
*   **20-day SMA:** 1042.56
*   **60-day SMA:** 931.17

**Analysis:**

The stock price is above all three moving averages (5-day, 20-day, and 60-day SMA), indicating an uptrend.  The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, further supporting this bullish trend. The market data show a slight price increase, suggesting continued positive momentum.

**3) RSI, PPO, and Divergence Analysis**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 55.59
*   **PPO:** -0.23
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent Divergence Change:** 5.8 (+) (Short-term Increase)
*   **Expected Return:** 49.2%

**Analysis:**

*   **MRI:** The MRI of 0.8 suggests a medium investment recommendation, indicating a moderate level of risk.
*   **RSI:** An RSI of 55.59 is neutral, not indicating overbought or oversold conditions.
*   **PPO:** A slightly negative PPO (-0.23) suggests that the short-term moving average is slightly below the long-term moving average, but the signal is weak.
*   **Hybrid Signal:** The hybrid signal recommends buying with 100% of cash, and the recommendation is "Very Safe" due to the MRI is 0.9.
*   **Divergence Change:** The recent increase in relative divergence suggests a short-term positive trend.
*   **Expected Return:** The high expected return (49.2%) suggests potential for substantial gains if held long-term.

**4) Recent News & Significant Events:**

*   **Stock Split Candidate:** Eli Lilly is considered a top stock split candidate for 2026.
*   **Wegovy Pill Approval & Competition:** News focuses on the potential impact of Novo Nordisk's oral Wegovy approval and how it compares to Eli Lilly.
*   **Inluriyo (imlunestrant) Study:** Updated results from a Phase 3 study of Inluriyo were released.
*   **Analyst Consensus:**

    *   **Key:** Buy
    *   **Mean:** 1.70 (~Buy)
    *   **Opinions:** 27
    *   **Target Price:** 1093.22 (avg) / 1500.00 (high) / 770.00 (low)
*   **Recent Rating Changes:**

    *   • [0] : → ()
    *   • [1] : → ()
    *   • [2] : → ()
    *   • [3] : → ()

**Analysis:**

The news indicates a mix of positive and competitive factors.  The stock split potential suggests confidence in future growth.  Competition in the weight loss drug market (Wegovy vs. LLY's offerings) is a key theme. The Inluriyo study release highlights the company's ongoing research and development efforts. Analyst consensus is strongly bullish with a target price above the current level. Recent rating changes are unavailable, indicating that no changes has happened recently.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-30 | 6.22 | 17.60 B$   |
| 2025-08-07 | 6.30 | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2025-10-30 | 1.08 | 11.44 B$   |

**Analysis:**

The table shows a clear trend of increasing revenue and EPS over the recent quarters. There is typo in the table: 2024-10-30 and 2025-10-30 has the same value. Revenue growth has been consistent, and EPS has also increased significantly. This demonstrates strong financial performance.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $23.79B    | 23.46% |
| 2025-06-30   | $18.27B    | 30.98% |
| 2025-03-31   | $15.76B    | 17.50% |
| 2024-12-31   | $14.19B    | 31.07% |
| 2024-09-30   | $14.24B    | 6.81%  |

**Analysis:**

*   **Revenue and Profitability:**  Revenue has grown consistently over the past five quarters, and the profit margin has remained exceptionally high, consistently above 80%. This demonstrates the company's pricing power and efficient cost management.
*   **Capital and Profitability:**  Equity has increased significantly, indicating strong earnings retention.  ROE (Return on Equity) is variable but generally high, reflecting efficient use of shareholder capital.

**7) Comprehensive Analysis (Summary)**

Eli Lilly (LLY) is exhibiting strong financial performance and positive market sentiment.  Key takeaways:

*   **Outperformance:** LLY has significantly outperformed the S&P 500.
*   **Growth:** Strong CAGR and increasing revenue/EPS demonstrate robust growth.
*   **Profitability:** Exceptionally high profit margins and solid ROE highlight profitability.
*   **Bullish Sentiment:** Analyst consensus is "Buy," and the stock split potential suggests continued confidence.
*   **Risk Factors:** The high MDD indicate high volatility. Competition in the weight loss drug market poses a risk.
*   **Investment Recommendation:** Based on the MRI and hybrid signal, a medium to high investment in LLY is recommended. However, investors should be aware of the high volitality.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.